This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2023 Aug 15;330(7):593-594.

doi: 10.1001/jama.2023.11056.

340B-Where Do We Go From Here?

Sanjay Kishore^{1

2}, Rahul K Nayak³, Aaron S Kesselheim^{4

5}

Affiliations

Affiliations

¹ The Equal Justice Initiative, Montgomery, Alabama.
² The University of Alabama at Birmingham.
³ Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.
⁴ Program on Regulation, Therapeutics, and Law (PORTAL), Brigham and Women's Hospital, Boston, Massachusetts.
⁵ Harvard Medical School, Boston, Massachusetts.

PMID: 37505512
DOI: 10.1001/jama.2023.11056

340B-Where Do We Go From Here?

Sanjay Kishore et al. JAMA. 2023.

. 2023 Aug 15;330(7):593-594.

doi: 10.1001/jama.2023.11056.

Authors

Sanjay Kishore^{1

2}, Rahul K Nayak³, Aaron S Kesselheim^{4

5}

Affiliations

¹ The Equal Justice Initiative, Montgomery, Alabama.
² The University of Alabama at Birmingham.
³ Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.
⁴ Program on Regulation, Therapeutics, and Law (PORTAL), Brigham and Women's Hospital, Boston, Massachusetts.
⁵ Harvard Medical School, Boston, Massachusetts.

PMID: 37505512
DOI: 10.1001/jama.2023.11056

No abstract available

Plain language summary

This Viewpoint summarizes inefficiencies in the 340B program and provides suggestions for equitable reform that will potentially benefit patients.

PubMed Disclaimer

Similar articles

340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation. Final rule.
Health Resources and Services Administration, Department of Health and Human Services (HHS). Health Resources and Services Administration, Department of Health and Human Services (HHS). Fed Regist. 2017 Jan 5;82(3):1210-30. Fed Regist. 2017. PMID: 28071875
Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016.
Conti RM, Nikpay SS, Buntin MB. Conti RM, et al. JAMA Netw Open. 2019 Oct 2;2(10):e1914141. doi: 10.1001/jamanetworkopen.2019.14141. JAMA Netw Open. 2019. PMID: 31664442 Free PMC article.
Using 340B drug discounts to provide a financially sustainable medication discharge service.
Wu T, Williams C, Vranek K, Mattingly TJ 2nd. Wu T, et al. Res Social Adm Pharm. 2019 Jan;15(1):114-116. doi: 10.1016/j.sapharm.2018.03.065. Epub 2018 Mar 27. Res Social Adm Pharm. 2019. PMID: 29606609
The 340b Program, Contract Pharmacies, Hospitals, and Patients: An Evolving Relationship Impacting Health Care Delivery.
Ruley M, Belcher M, Sayre H, Coustasse A. Ruley M, et al. Health Care Manag (Frederick). 2019 Oct/Dec;38(4):311-321. doi: 10.1097/HCM.0000000000000279. Health Care Manag (Frederick). 2019. PMID: 31663869
The Reach of the 340B Drug Pricing Program.
Albrecht J, Mudahar S. Albrecht J, et al. JAMA Dermatol. 2015 Sep;151(9):923-4. doi: 10.1001/jamadermatol.2015.1005. JAMA Dermatol. 2015. PMID: 25993384 Review. No abstract available.

See all similar articles

Cited by

Interpreting 340B contract pharmacy growth: who really benefits?
Mattingly TJ 2nd. Mattingly TJ 2nd. Health Aff Sch. 2023 Dec 9;2(1):qxad076. doi: 10.1093/haschl/qxad076. eCollection 2024 Jan. Health Aff Sch. 2023. PMID: 38756400 Free PMC article. No abstract available.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems